MCID: CHG001
MIFTS: 67

Chagas Disease malady

Categories: Rare diseases, Infectious diseases, Neuronal diseases

Aliases & Classifications for Chagas Disease

Aliases & Descriptions for Chagas Disease:

Name: Chagas Disease 12 50 56 52 41 3 14 69
American Trypanosomiasis 12 50 56 3
Chagas' Disease with Digestive System Involvement 12
Chagas' Disease with Nervous System Involvement 12
Chagas' Disease with Other Organ Involvement 12
South American Trypanosomiasis 50
New World Trypanosomiasis 50
Chagas' Disease 12

Characteristics:

Orphanet epidemiological data:

56
american trypanosomiasis
Inheritance: Not applicable; Prevalence: 6-9/10000 (United States); Age of onset: All ages; Age of death: any age;

Classifications:

Orphanet: 56  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:12140
ICD9CM 35 086.2
Orphanet 56 ORPHA3386
UMLS via Orphanet 70 C0041234
ICD10 via Orphanet 34 B57.0 B57.1 B57.2 more
UMLS 69 C0007932

Summaries for Chagas Disease

MedlinePlus : 41 chagas disease is caused by a parasite. it is common in latin america but not in the united states. infected blood-sucking bugs, sometimes called kissing bugs, spread it. when the bug bites you, usually on your face, it leaves behind infected waste. you can get the infection if you rub it in your eyes or nose, the bite wound or a cut. the disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. if you notice symptoms, they might include fever flu-like symptoms a rash a swollen eyelid these early symptoms usually go away. however, if you don't treat the infection, it stays in your body. later, it can cause serious intestinal and heart problems. a physical exam and blood tests can diagnose it. you may also need tests to see whether the disease has affected your intestines and heart. medicines can kill the parasite, especially early on. you can also treat related problems. for example, a pacemaker helps with certain heart complications. there are no vaccines or medicines to prevent chagas disease. if you travel to areas where it occurs, you are at higher risk if you sleep outdoors or in poor housing conditions. it is important to use insecticides to prevent bites, and practice food safety. centers for disease control and prevention

MalaCards based summary : Chagas Disease, also known as american trypanosomiasis, is related to hepatitis and congestive heart failure, and has symptoms including myalgia, dyspnea and fever. An important gene associated with Chagas Disease is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Chagas disease (American trypanosomiasis) and Innate Immune System. The drugs Carvedilol and Enalapril have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and eye, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and cardiovascular system

NIH Rare Diseases : 50 chagas disease is caused by the parasite, trypanosoma cruzi. when a triatomine bug (commonly known as a "kissing bug") infected with this parasite bites you, usually on your face, it leaves behind infected waste which can be spread into your eyes, nose, or a wound. chagas disease can also spread through contaminated food, a blood transfusion, a donated organ or from mother to baby during pregnancy. symptoms can include fever, flu-like symptoms, a rash or swollen eyelid. early symptoms usually go away but if not treated, the infection can later cause serious intestinal and heart problems. chagas disease is common in latin america but not in the united states. last updated: 3/4/2014

CDC : 3 Chagas disease is named after the Brazilian physician Carlos Chagas, who discovered the disease in 1909. It is caused by the parasite Trypanosoma cruzi, which is transmitted to animals and people by insect vectors and is found only in the Americas (mainly, in rural areas of Latin America where poverty is widespread). Chagas disease (T. cruzi infection) is also referred to as American trypanosomiasis.

Disease Ontology : 12 A trypanosomiasis that is a tropical parasitic disease caused by the flagellate protozoan Trypanosoma cruzi, which is transmitted to humans and other mammals by an insect vector, the blood-sucking assassin bugs of the subfamily Triatominae (family Reduviidae), most commonly species belonging to the Triatoma, Rhodnius, and Panstrongylus genera. The symptoms include fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, vomiting, swelling of the eyelids and myocarditis.

Wikipedia : 71 Chagas disease, also known as American trypanosomiasis, is a tropical parasitic disease caused by the... more...

Related Diseases for Chagas Disease

Diseases related to Chagas Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 362)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.7 IFNG IL10 IL2 IL6 TNF
2 congestive heart failure 29.6 IFNG IL10 IL2 IL6 TNF
3 neuropathy 29.6 CXCL8 IL1B IL6 TLR4 TNF
4 trypanosomiasis 11.5
5 pyridoxal 5'-phosphate-dependent epilepsy 10.4 IL10 TNF
6 intussusception 10.4 IL1B TNF
7 refractory celiac disease 10.4 IL10 TGFB1
8 cardiomyopathy 10.4
9 autosomal dominant deafness-onychodystrophy syndrome 10.4 IFNG IL2 TNF
10 urethral intrinsic sphincter deficiency 10.4 CCL2 IFNG TNF
11 neurotic disorder 10.4 IFNG IL10 TNF
12 stocco dos santos syndrome 10.4 IFNG IL1B TNF
13 congenital hypothyroidism 10.3 IL10 TLR2 TNF
14 spotted fever 10.3 TLR2 TLR4 TNF
15 distal trisomy 14q 10.3 IFNG TGFB1 TNF
16 parametritis 10.3 IFNG IL2 TNF
17 steatitis 10.3 IL2 TNF
18 paralytic poliomyelitis 10.3 IFNG IL2 TLR4
19 aseptic meningitis 10.3 TLR2 TLR4 TNF
20 rosacea 10.3 IFNG IL10 IL1B
21 transient tic disorder 10.3 IL10 IL6 TNF
22 discharging ear 10.3 IFNG IL10 TGFB1
23 parasitic ichthyosporea infectious disease 10.3 TLR2 TLR4 TNF
24 polyarteritis nodosa 10.3 IFNG TLR2 TLR4
25 venezuelan hemorrhagic fever 10.3 IFNG IL2 TNF
26 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.3 CCR5 IFNG TNF
27 idiopathic hypertrophic pachymeningitis 10.3 IL10 NOS2 TNF
28 pseudoainhum 10.3 IL1B TLR2 TLR4
29 ethmoid sinus cancer 10.3 IFNG IL1B TLR4
30 conidiobolomycosis 10.3 CXCL8 IL10 TNF
31 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
32 lepromatous leprosy 10.3 IFNG IL10 IL6
33 phlyctenulosis 10.3 IL10 IL6 TNF
34 malignant oculomotor nerve tumor 10.3 CCL2 IFNG TGFB1
35 megaloblastic anemia 10.3 IL10 IL1B TLR4
36 reproductive system disease 10.3 IL10 IL6 TLR2
37 anal atresia, hypospadias, and penoscrotal inversion 10.3 CCL2 IFNG TLR2
38 multiple mitochondrial dysfunctions syndrome 10.3 IFNG IL10 IL6
39 primary ciliary dyskinesia 10.3 IL10 IL6 TNF
40 handl syndrome 10.3 CXCL8 TLR2 TNF
41 bipolar i disorder 10.3 IL1B IL6 TNF
42 coronary arterial fistulas 10.3 CXCL8 IL10 TLR4
43 human immunodeficiency virus infectious disease 10.3 IL1B IL6 TNF
44 measles 10.3 IL1B IL6 TNF
45 leukoplakia of vagina 10.3 IL6 TLR2 TNF
46 endogenous depression 10.3 IL2 TLR2 TNF
47 preaxial polydactyly of fingers 10.3 IL6 TGFB1 TNF
48 dextrocardia 10.3 IL1B IL6 TNF
49 oropharynx cancer 10.3 IFNG IL10 IL2
50 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.3 IFNG IL10 IL2 TNF

Graphical network of the top 20 diseases related to Chagas Disease:



Diseases related to Chagas Disease

Symptoms & Phenotypes for Chagas Disease

Human phenotypes related to Chagas Disease:

56 32 (show all 27)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myalgia 56 32 Frequent (79-30%) HP:0003326
2 dyspnea 56 32 Frequent (79-30%) HP:0002094
3 fever 56 32 Frequent (79-30%) HP:0001945
4 headache 56 32 Frequent (79-30%) HP:0002315
5 abdominal pain 56 32 Frequent (79-30%) HP:0002027
6 diarrhea 56 32 Frequent (79-30%) HP:0002014
7 periorbital edema 56 32 Frequent (79-30%) HP:0100539
8 encephalitis 56 32 Very rare (<4-1%) HP:0002383
9 splenomegaly 56 32 Frequent (79-30%) HP:0001744
10 hepatomegaly 56 32 Frequent (79-30%) HP:0002240
11 arrhythmia 56 32 Frequent (79-30%) HP:0011675
12 thromboembolism 56 32 Frequent (79-30%) HP:0001907
13 pallor 56 32 Frequent (79-30%) HP:0000980
14 peripheral neuropathy 56 32 Very rare (<4-1%) HP:0009830
15 congestive heart failure 56 32 Occasional (29-5%) HP:0001635
16 cardiomyopathy 56 32 Frequent (79-30%) HP:0001638
17 aganglionic megacolon 56 32 Occasional (29-5%) HP:0002251
18 achalasia 56 32 Occasional (29-5%) HP:0002571
19 myocarditis 56 32 Frequent (79-30%) HP:0012819
20 skin rash 56 32 Frequent (79-30%) HP:0000988
21 cough 56 32 Frequent (79-30%) HP:0012735
22 lymphadenopathy 56 32 Frequent (79-30%) HP:0002716
23 abnormal large intestine physiology 56 32 Occasional (29-5%) HP:0012700
24 localized skin lesion 56 32 Frequent (79-30%) HP:0011355
25 autoimmune antibody positivity 56 32 Frequent (79-30%) HP:0030057
26 edema 56 Frequent (79-30%)
27 abnormality of the nervous system 56 Very rare (<4-1%)

UMLS symptoms related to Chagas Disease:


fever, pruritus

GenomeRNAi Phenotypes related to Chagas Disease according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.77 NOS2 TGFB1 TNF CXCL8 IL10 IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.77 NOS2 TGFB1 TNF CXCL8 IL10 IL1B

MGI Mouse Phenotypes related to Chagas Disease:

44 (show all 22)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.47 TGFB1 TLR2 TLR4 TNF ADRB1 CALR
2 homeostasis/metabolism MP:0005376 10.43 IL6 NOS2 SMAD2 TGFB1 TLR2 TLR4
3 immune system MP:0005387 10.39 CCR5 CYP51A1 IFNG IL10 IL12B IL1B
4 digestive/alimentary MP:0005381 10.38 CCR5 CYP51A1 IFNG IL10 IL12B IL2
5 cellular MP:0005384 10.36 CALR CCR5 IFNG IL10 IL2 IL6
6 growth/size/body region MP:0005378 10.36 CYP51A1 IFNG IL10 IL2 IL6 NOS2
7 mortality/aging MP:0010768 10.36 CYP51A1 IFNG IL10 IL12B IL1B IL2
8 hematopoietic system MP:0005397 10.35 CCR5 IFNG IL10 IL12B IL1B IL2
9 behavior/neurological MP:0005386 10.34 CCR5 IFNG IL10 IL2 IL6 NOS2
10 endocrine/exocrine gland MP:0005379 10.26 TGFB1 TLR2 TNF ADRB1 IFNG IL10
11 liver/biliary system MP:0005370 10.22 CCR5 IFNG IL10 IL2 IL6 NOS2
12 neoplasm MP:0002006 10.22 SMAD2 TGFB1 TLR2 TLR4 TNF CCR5
13 muscle MP:0005369 10.21 ADRB1 CALR CCR5 CYP51A1 IFNG IL10
14 integument MP:0010771 10.19 IFNG IL10 IL1B IL6 NOS2 SMAD2
15 craniofacial MP:0005382 10.18 CYP51A1 IFNG IL10 IL12B NOS2 SMAD2
16 adipose tissue MP:0005375 10.15 IL6 NOS2 TGFB1 TLR2 TLR4 TNF
17 nervous system MP:0003631 10.15 CALR CCR5 IFNG IL10 IL1B IL6
18 reproductive system MP:0005389 9.96 CCR5 IFNG IL10 IL2 IL6 NOS2
19 no phenotypic analysis MP:0003012 9.92 ADRB1 CCR5 CYP51A1 IFNG IL10 IL2
20 respiratory system MP:0005388 9.9 IL10 IL12B IL2 IL6 NOS2 SMAD2
21 skeleton MP:0005390 9.77 ADRB1 CYP51A1 IFNG IL10 IL12B IL1B
22 vision/eye MP:0005391 9.32 IL10 IL2 IL6 NOS2 SMAD2 TGFB1

Drugs & Therapeutics for Chagas Disease

Drugs for Chagas Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 176)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
2
Enalapril Approved, Vet_approved Phase 4 75847-73-3 5362032 40466924
3
Enalaprilat Approved Phase 4 76420-72-9 6917719
4
Warfarin Approved Phase 4 81-81-2 6691 54678486
5
Efavirenz Approved, Investigational Phase 4,Phase 3,Phase 2 154598-52-4 64139
6
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
7
Rifampin Approved Phase 4,Phase 3,Phase 2 13292-46-1 5458213 5381226
8
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3 155213-67-5 392622
9
Emtricitabine Approved, Investigational Phase 4,Phase 3 143491-57-0 60877
10
Tenofovir Approved, Investigational Phase 4,Phase 3,Phase 2 147127-20-6 464205
11
Ethambutol Approved Phase 4,Phase 3,Phase 2 74-55-5 3279 14052
12
Isoniazid Approved Phase 4,Phase 3,Phase 2 54-85-3 3767
13
Pyrazinamide Approved Phase 4,Phase 3,Phase 2 98-96-4 1046
14
Didanosine Approved Phase 4,Phase 3 69655-05-6 50599
15
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2 134678-17-4 60825
16
Zidovudine Approved Phase 4,Phase 3,Phase 2 30516-87-1 35370
17
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
18
Darunavir Approved Phase 4 635728-49-3, 206361-99-1 213039
19
Etravirine Approved Phase 4 269055-15-4 193962
20
Pyridoxal Approved, Nutraceutical Phase 4,Phase 3,Phase 2 66-72-8 1050
21
Pyridoxine Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054
22 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Antiparasitic Agents Phase 4,Phase 3,Phase 2,Phase 1
24 Antiprotozoal Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Benzonidazole Phase 4,Phase 3,Phase 2
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2
27 Adrenergic Agents Phase 4,Phase 3
28 Adrenergic alpha-1 Receptor Antagonists Phase 4
29 Adrenergic alpha-Antagonists Phase 4
30 Adrenergic Antagonists Phase 4,Phase 3
31 Adrenergic beta-Antagonists Phase 4,Phase 3
32 Angiotensin-Converting Enzyme Inhibitors Phase 4
33 Antihypertensive Agents Phase 4,Phase 3
34 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
35 Natriuretic Peptide, Brain Phase 4
36 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
37
protease inhibitors Phase 4,Phase 2,Phase 3
38 Vasodilator Agents Phase 4
39 Anticoagulants Phase 4
40 Anti-Bacterial Agents Phase 4,Phase 2,Phase 3
41 Antibiotics, Antitubercular Phase 4,Phase 2,Phase 3
42 Anti-HIV Agents Phase 4,Phase 2,Phase 3
43 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3
44 Antitubercular Agents Phase 4,Phase 2,Phase 3
45 Antiviral Agents Phase 4,Phase 2,Phase 3
46 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2
47 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 2,Phase 3
48 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2,Phase 3
49 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2
50 rifamycin SV Phase 4

Interventional clinical trials:

(show top 50) (show all 106)
id Name Status NCT ID Phase
1 Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease Unknown status NCT01678599 Phase 4
2 Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease Unknown status NCT01549236 Phase 4
3 Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease Completed NCT01755403 Phase 4
4 Exercise Training in Chagas Cardiomyopathy Completed NCT01006473 Phase 4
5 A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy Completed NCT01557140 Phase 4
6 Outcomes of an Anticoagulation Clinic in an University Hospital Completed NCT01006486 Phase 4
7 An Evaluation of the Pharmacological Interaction of Lopinavir/r and Rifampin Completed NCT00771498 Phase 4
8 Immediate Versus Deferred Start of Anti-HIV Therapy in HIV-Infected Adults Being Treated for Tuberculosis Completed NCT00108862 Phase 4
9 Pharmacokinetics of the Tablet Formulation of Lopinavir/r as Standard and Increased Dosage During Pregnancy Completed NCT00605098 Phase 4
10 HIV Treatment Reinitiation in Women Who Received Anti-HIV Drugs to Prevent Mother-to-Child Transmission of HIV Completed NCT00442962 Phase 4
11 REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment Completed NCT01380080 Phase 4
12 Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings Completed NCT00084136 Phase 4
13 Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS) Recruiting NCT01650792 Phase 4
14 A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure Active, not recruiting NCT01641367 Phase 4
15 Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease Terminated NCT01539161 Phase 4
16 Randomized Clinical Trial to Assess the Efficacy and Safety of Concomitant Use of Rifampicin and Efavirenz 600 X 800mg Terminated NCT00533390 Phase 4
17 BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease Unknown status NCT00123916 Phase 3
18 Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial Completed NCT02386358 Phase 3
19 Cardiac Rehabilitation in Chagas Heart Failure Completed NCT02516293 Phase 2, Phase 3
20 Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity Completed NCT00323973 Phase 3
21 Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor Completed NCT00038519 Phase 2, Phase 3
22 Preventing Sexual Transmission of HIV With Anti-HIV Drugs Completed NCT00074581 Phase 3
23 Quadrivalent HPV Vaccine to Prevent Anal HPV in HIV-infected Men and Women Completed NCT01461096 Phase 3
24 Study of Options for Second-Line Effective Combination Therapy (SELECT) Completed NCT01352715 Phase 3
25 A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment Completed NCT00004581 Phase 3
26 A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy Completed NCT00004583 Phase 3
27 Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults Completed NCT01108510 Phase 3
28 Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects Completed NCT00146328 Phase 2, Phase 3
29 Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. Completed NCT01991899 Phase 3
30 Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease Recruiting NCT02625974 Phase 3
31 Selenium Treatment and Chagasic Cardiopathy (STCC) Recruiting NCT00875173 Phase 3
32 CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY) Recruiting NCT02369978 Phase 2, Phase 3
33 Low Antimonial Dosage in American Mucosal Leishmaniasis Recruiting NCT01301937 Phase 2, Phase 3
34 Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults Recruiting NCT02344290 Phase 3
35 TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens Recruiting NCT02410772 Phase 3
36 Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment Recruiting NCT02548351 Phase 3
37 Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS Recruiting NCT01435018 Phase 3
38 Physical Exercise Program in Chronic Chagas Heart Disease Active, not recruiting NCT02517632 Phase 3
39 Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis Active, not recruiting NCT01301924 Phase 2, Phase 3
40 Evaluating the Safety and Effectiveness of Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals With Latent Tuberculosis Infection Active, not recruiting NCT01404312 Phase 3
41 Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma Active, not recruiting NCT01352117 Phase 3
42 Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment Active, not recruiting NCT01818596 Phase 3
43 Can Valacyclovir Delay the Need for Initiation of Human Immunodeficiency Virus (HIV) Treatment in HIV-infected Individuals? Active, not recruiting NCT00860977 Phase 3
44 Switching From a TDF-Containing Combination Regimen to a TAF-Containing Fixed Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Positive Participants Active, not recruiting NCT01815736 Phase 3
45 Treatment of Asymptomatic Toxocariasis With Albendazole in Children Active, not recruiting NCT00755560 Phase 3
46 Randomized Clinical Trial of Three Drug Combinations for Late-Stage Gambiense Human African Trypanosomiasis Terminated NCT00330148 Phase 3
47 Cell Therapy in Chagas Cardiomyopathy Terminated NCT00349271 Phase 3
48 Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease Unknown status NCT01489228 Phase 2
49 Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults Unknown status NCT01155037 Phase 2
50 A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267) Completed NCT01377480 Phase 2

Search NIH Clinical Center for Chagas Disease

Genetic Tests for Chagas Disease

Anatomical Context for Chagas Disease

MalaCards organs/tissues related to Chagas Disease:

39
Heart, Testes, Eye, Colon, Lymph Node, T Cells, Skin

Publications for Chagas Disease

Articles related to Chagas Disease:

(show top 50) (show all 806)
id Title Authors Year
1
Triatoma vitticeps subcomplex (Hemiptera, Reduviidae, Triatominae): a new grouping of Chagas disease vectors from South America. ( 28407782 )
2017
2
Interdisciplinary approach at the primary healthcare level for Bolivian immigrants with Chagas disease in the city of SALo Paulo. ( 28333923 )
2017
3
Chagas disease in Europe: A review for the internist in the globalized world. ( 28502864 )
2017
4
Challenges in the management of Chagas disease in Latin-American migrants in Europe. ( 28428122 )
2017
5
Molecular and serological detection of Trypanosoma cruzi in dogs (Canis lupus familiaris) suggests potential transmission risk in areas of recent acute Chagas disease outbreaks in Colombia. ( 28532988 )
2017
6
Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram. ( 28056014 )
2017
7
Chagas disease: national survey of seroprevalence in children under five years of age conducted in 2008. ( 28443980 )
2017
8
Modeling Chagas disease in Chile: From vector to congenital transmission. ( 28435013 )
2017
9
Temporal Variation in the Abundance and Timing of Daily Activity of Chagas Disease Vector Triatoma gerstaeckeri (StAYl, 1859) in a Natural Habitat in the Lower Rio Grande Valley, South Texas. ( 28530845 )
2017
10
Ten years of Chagas disease research: Looking back to achievements, looking ahead to challenges. ( 28426735 )
2017
11
Towards improving early diagnosis of congenital Chagas disease in an endemic setting. ( 28369287 )
2017
12
Chagas disease immunogenetics: elusive markers of disease progression. ( 28388241 )
2017
13
The process of lipid storage in insect oocytes: The involvement of I^-chain of ATP synthase in lipophorin-mediated lipid transfer in the chagas' disease vector Panstrongylus megistus (Hemiptera: Reduviidae). ( 27983943 )
2017
14
Chagas disease research and development: Is there light at the end of the tunnel? ( 28066534 )
2017
15
Participation of TLR2 and TLR4 in Cytokines Production by Patients with Symptomatic and Asymptomatic Chronic Chagas Disease. ( 27783847 )
2017
16
Understanding transmissibility patterns of Chagas disease through complex vector-host networks. ( 28077180 )
2017
17
Autochthonous Chagas disease in the southern United States: A case report of suspected residential and military exposures. ( 28418113 )
2017
18
Access to Chagas disease treatment in non-endemic countries: the case of Spain. ( 28495262 )
2017
19
Genetic Polymorphisms of IL17 and Chagas Disease in the South and Southeast of Brazil. ( 28470012 )
2017
20
The Evolutionary Origin of Diversity in Chagas Disease Vectors. ( 27986547 )
2017
21
Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources? ( 28056025 )
2017
22
The Prevalence of Trypanosoma cruzi, the Causal Agent of Chagas Disease, in Texas Rodent Populations. ( 28091763 )
2017
23
Unraveling Chagas disease transmission through the oral route: Gateways to Trypanosoma cruzi infection and target tissues. ( 28379959 )
2017
24
The Prevalence of Chagas Disease Among Latin American Immigrants with Pacemakers in Los Angeles, California. ( 28500812 )
2017
25
Automated identification of insect vectors of Chagas disease in Brazil and Mexico: the Virtual Vector Lab. ( 28439451 )
2017
26
Evaluation of P2X7 receptor expression in peripheral lymphocytes and immune profile from patients with indeterminate form of Chagas disease. ( 28062289 )
2017
27
Leishmanicidal and Trypanocidal Activity of Metal Complexes with 1,2,4-Triazolo[1,5-a]pyrimidines: Insights on their Therapeutic Potential against Leishmaniasis and Chagas Disease. ( 28521698 )
2017
28
Regarding Perspective Piece from July 2016 "What Do We Know About Chagas Disease in the United States?" ( 28471741 )
2017
29
Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis. ( 28369081 )
2017
30
The molecular sensory machinery of a Chagas disease vector: expression changes through imaginal moult and sexually dimorphic features. ( 28059141 )
2017
31
Performance Assessment of Four Chimeric Trypanosoma cruzi Antigens Based on Antigen-Antibody Detection for Diagnosis of Chronic Chagas Disease. ( 27517281 )
2016
32
Advances and Progress in Chagas Disease Drug Discovery. ( 27072717 )
2016
33
Community resilience and Chagas disease in a rural region of Mexico. ( 27509012 )
2016
34
Serological Diagnosis of Chronic Chagas Disease: Is It Time for a Change? ( 27053668 )
2016
35
Orally-transmitted Chagas disease. ( 27993415 )
2016
36
Acute colonic complications in a patient with Chagas disease. ( 27128343 )
2016
37
Oesophageal motility disorders in infected immigrants with Chagas disease in a non-endemic European area. ( 27536373 )
2016
38
IL18 Gene Variants Influence the Susceptibility to Chagas Disease. ( 27027876 )
2016
39
Morphological and Genetic Differentiation within the Southernmost Vector of Chagas Disease: Triatoma patagonica (Hemiptera - Reduviidae). ( 28005972 )
2016
40
PHARMACOKINETICS OF BENZNIDAZOLE IN CHAGAS DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. ( 27550362 )
2016
41
Scrutinizing the Biomarkers for the Neglected Chagas Disease: How Remarkable! ( 27563302 )
2016
42
Trypanosoma cruzi Infection Prevalence and Bloodmeal Analysis in Triatomine Vectors of Chagas Disease From Rural Peridomestic Locations in Texas, 2013-2014. ( 27106934 )
2016
43
Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness. ( 27501246 )
2016
44
New cases of Chagas disease in a rural area of Northeast Brazilian. ( 27192597 )
2016
45
Chronic Heart Disease after Treatment of Oral Acute Chagas Disease. ( 27627643 )
2016
46
Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens. ( 28001218 )
2016
47
Chagas' disease in Aboriginal and Creole communities from the Gran Chaco Region of Argentina: Seroprevalence and molecular parasitological characterization. ( 27057620 )
2016
48
Flavonoids and Chagas' disease: the story so far! ( 27558676 )
2016
49
Analysis of Regional Left Ventricular Strain in Patients with Chagas Disease and Normal Left Ventricular Systolic Function. ( 27086044 )
2016
50
A Deep Insight into the Sialome of Rhodnius neglectus, a Vector of Chagas Disease. ( 27129103 )
2016

Variations for Chagas Disease

Expression for Chagas Disease

Search GEO for disease gene expression data for Chagas Disease.

Pathways for Chagas Disease

Pathways related to Chagas Disease according to KEGG:

37
id Name Kegg Source Accession
1 Chagas disease (American trypanosomiasis) hsa05142

Pathways related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.18 CALR CCL2 CCR5 CXCL8 IFNG IL10
2
Show member pathways
14 ADRB1 CCL2 CCR5 CXCL8 IL10 IL12B
3
Show member pathways
13.84 CCL2 CCR5 CXCL8 IFNG IL10 IL12B
4
Show member pathways
13.69 CCL2 CXCL8 IFNG IL10 IL12B IL1B
5
Show member pathways
13.6 CCL2 CCR5 CXCL8 IL10 IL12B IL1B
6
Show member pathways
13.54 CCL2 CCR5 CXCL8 IFNG IL10 IL12B
7
Show member pathways
13.47 CCL2 CCR5 CXCL8 IL10 IL12B IL1B
8
Show member pathways
13.16 CCL2 CXCL8 IL1B IL6 NOS2 TLR2
9
Show member pathways
13.11 CALR CCL2 CXCL8 IFNG IL10 IL12B
10
Show member pathways
13.08 CALR CXCL8 IFNG IL10 IL12B IL1B
11
Show member pathways
13.02 CCL2 CXCL8 IFNG IL12B IL1B IL2
12
Show member pathways
12.88 IL1B IL2 IL6 TGFB1 TLR2 TLR4
13
Show member pathways
12.87 CXCL8 IFNG IL12B IL1B IL6 TNF
14
Show member pathways
12.83 CCL2 IFNG IL10 IL12B IL1B IL2
15
Show member pathways
12.8 IFNG IL10 IL12B IL1B IL2 IL6
16 12.76 CXCL8 IL6 NOS2 SMAD2 TGFB1
17 12.74 CCL2 IFNG IL10 IL1B IL2 TLR2
18
Show member pathways
12.72 IFNG IL10 IL12B IL2 TNF
19
Show member pathways
12.7 IL12B IL1B TLR2 TLR4 TNF
20
Show member pathways
12.66 CCR5 IFNG IL10 IL1B IL2 IL6
21 12.61 CALR IL2 IL6 SMAD2 TGFB1 TNF
22
Show member pathways
12.56 CCL2 CXCL8 IFNG IL1B IL6 TLR2
23
Show member pathways
12.52 CCL2 IFNG IL1B IL2 IL6 TNF
24
Show member pathways
12.5 CXCL8 IFNG IL1B IL6 NOS2 TLR4
25 12.49 IL12B SMAD2 TGFB1 TLR2 TLR4 TNF
26
Show member pathways
12.48 CCR5 IFNG IL10 IL12B IL1B NOS2
27
Show member pathways
12.44 CXCL8 IFNG IL1B IL6 NOS2 TLR2
28 12.43 IFNG IL6 NOS2 SMAD2 TGFB1 TLR2
29 12.43 IFNG IL10 IL12B IL1B IL6 NOS2
30
Show member pathways
12.42 CXCL8 IL6 TLR2 TLR4 TNF
31
Show member pathways
12.4 CXCL8 IFNG IL10 IL12B IL1B IL2
32
Show member pathways
12.37 IFNG IL10 IL12B IL2 IL6
33 12.34 CXCL8 IL10 IL1B IL6 TNF
34
Show member pathways
12.3 ADRB1 IL6 TGFB1 TNF
35
Show member pathways
12.22 CCR5 IFNG IL12B IL1B IL2 NOS2
36 12.21 CCL2 IFNG IL1B TNF
37
Show member pathways
12.2 IL10 IL6 SMAD2 TGFB1
38 12.2 CCL2 CXCL8 IL10 IL12B IL1B IL6
39 12.18 IFNG IL10 IL2 IL6 TNF
40 12.17 IFNG IL1B TGFB1 TNF
41 12.16 CCL2 CXCL8 IL1B IL6 SMAD2 TGFB1
42
Show member pathways
12.16 IFNG IL12B IL1B IL6 SMAD2 TGFB1
43 12.16 CXCL8 IFNG IL10 IL12B IL1B IL6
44
Show member pathways
12.15 IL1B IL2 TLR2 TLR4
45 12.13 CXCL8 IFNG IL1B IL6 TGFB1
46
Show member pathways
12.13 IFNG IL10 IL12B IL1B IL2 IL6
47
Show member pathways
12.12 CXCL8 IL12B IL6 SMAD2 TGFB1 TLR4
48 12.1 CCL2 CXCL8 IFNG IL1B IL2 IL6
49 12.09 CCL2 IL1B IL6 TNF
50 12.08 CXCL8 IFNG IL1B IL6 NOS2 TLR4

GO Terms for Chagas Disease

Cellular components related to Chagas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.93 CALR CCL2 CXCL8 IFNG IL10 IL12B
2 cell surface GO:0009986 9.73 CALR CCR5 TGFB1 TLR2 TLR4 TNF
3 external side of plasma membrane GO:0009897 9.43 CALR CCR5 IFNG IL6 TLR4 TNF
4 extracellular space GO:0005615 9.4 CALR CCL2 CXCL8 IFNG IL10 IL12B

Biological processes related to Chagas Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 9.99 IFNG IL1B NOS2 TNF
2 neutrophil chemotaxis GO:0030593 9.99 CCL2 CXCL8 IFNG IL1B
3 positive regulation of inflammatory response GO:0050729 9.97 IL12B IL2 TLR2 TLR4
4 positive regulation of T cell proliferation GO:0042102 9.97 IFNG IL12B IL1B IL2 IL6
5 positive regulation of gene expression GO:0010628 9.97 CALR IFNG IL1B IL6 SMAD2 TGFB1
6 response to wounding GO:0009611 9.96 CCL2 IL6 TGFB1
7 cellular response to mechanical stimulus GO:0071260 9.96 IL1B TGFB1 TLR4
8 cellular response to interleukin-1 GO:0071347 9.96 CCL2 CXCL8 IL6
9 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.96 IL6 TGFB1 TNF
10 humoral immune response GO:0006959 9.96 CCL2 IFNG IL6 TNF
11 defense response to Gram-negative bacterium GO:0050829 9.96 IL12B IL6 NOS2 TLR4
12 chemokine-mediated signaling pathway GO:0070098 9.95 CCL2 CCR5 CXCL8
13 defense response to Gram-positive bacterium GO:0050830 9.95 IL6 TLR2 TNF
14 response to insulin GO:0032868 9.95 IL10 IL6 TLR2
15 positive regulation of JNK cascade GO:0046330 9.95 IL1B TLR4 TNF
16 cellular response to drug GO:0035690 9.95 CCL2 IL1B NOS2
17 positive regulation of cell adhesion GO:0045785 9.95 CCL2 IFNG IL12B TNF
18 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.95 IFNG IL12B IL2 IL6
19 response to lipopolysaccharide GO:0032496 9.95 CCL2 IL10 IL1B IL6 NOS2 TLR2
20 cellular response to interferon-gamma GO:0071346 9.94 CCL2 IL12B NOS2
21 negative regulation of fat cell differentiation GO:0045599 9.92 IL6 TGFB1 TNF
22 extrinsic apoptotic signaling pathway GO:0097191 9.92 IFNG TGFB1 TNF
23 response to progesterone GO:0032570 9.92 CCL2 TGFB1 TLR2
24 response to bacterium GO:0009617 9.92 CCL2 IL6 NOS2 TLR4
25 protein kinase B signaling GO:0043491 9.92 CCL2 IL1B TGFB1 TNF
26 cellular response to estradiol stimulus GO:0071392 9.91 CCL2 IL10 IL6
27 cellular response to dexamethasone stimulus GO:0071549 9.91 CCL2 IL6 TGFB1
28 positive regulation of interleukin-8 production GO:0032757 9.91 IL1B TLR2 TLR4 TNF
29 positive regulation of tumor necrosis factor production GO:0032760 9.91 CCL2 IFNG IL12B TLR2 TLR4
30 positive regulation of phagocytosis GO:0050766 9.9 CALR IL1B TNF
31 protein import into nucleus, translocation GO:0000060 9.9 IFNG TGFB1 TNF
32 negative regulation of mitotic cell cycle GO:0045930 9.9 IL10 TGFB1 TNF
33 positive regulation of interleukin-12 production GO:0032735 9.9 IFNG IL12B TLR2 TLR4
34 negative regulation of interleukin-6 production GO:0032715 9.89 IL10 TLR4 TNF
35 positive regulation of protein complex assembly GO:0031334 9.89 IFNG TGFB1 TNF
36 positive regulation of interleukin-10 production GO:0032733 9.89 IL12B TLR2 TLR4
37 positive regulation of interferon-gamma production GO:0032729 9.89 IL12B IL1B IL2 TLR4 TNF
38 positive regulation of osteoclast differentiation GO:0045672 9.88 IFNG IL12B TNF
39 defense response to protozoan GO:0042832 9.88 IFNG IL10 IL12B IL6
40 positive regulation of interleukin-6 production GO:0032755 9.88 IL1B IL6 TLR2 TLR4 TNF
41 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.87 IFNG IL1B TNF
42 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.86 CCL2 TLR2 TLR4
43 response to molecule of bacterial origin GO:0002237 9.85 CXCL8 IL10 TLR2
44 positive regulation of interleukin-17 production GO:0032740 9.85 IL12B IL2 TGFB1
45 positive regulation of chemokine production GO:0032722 9.85 IL6 TLR2 TLR4 TNF
46 positive regulation of nitric oxide biosynthetic process GO:0045429 9.85 IFNG IL1B IL6 TLR4 TNF
47 inflammatory response GO:0006954 9.85 CCL2 CCR5 CXCL8 IL10 IL1B IL6
48 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.83 IL10 IL1B TNF
49 negative regulation of growth of symbiont in host GO:0044130 9.83 IFNG IL10 IL12B TNF
50 positive regulation of chemokine biosynthetic process GO:0045080 9.82 IFNG IL1B TNF

Molecular functions related to Chagas Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.35 IL10 IL12B IL2 IL6 TGFB1
2 cytokine activity GO:0005125 9.32 CCL2 CXCL8 IFNG IL10 IL12B IL1B
3 type I transforming growth factor beta receptor binding GO:0034713 9.26 SMAD2 TGFB1
4 lipopolysaccharide receptor activity GO:0001875 9.16 TLR2 TLR4

Sources for Chagas Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....